^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TNFRSF8 positive

i
Other names: TNFRSF8, TNF Receptor Superfamily Member 8, Tumor Necrosis Factor Receptor Superfamily Member 8, Lymphocyte Activation Antigen CD30, CD30L Receptor, Ki-1 Antigen, D1S166E, CD30, Tumor Necrosis Factor Receptor Superfamily, Member 8, Cytokine Receptor CD30, CD30 Antigen, TNFRSF8, Ki-1
Entrez ID:
Related biomarkers:
15d
OSU-17204: Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma (clinicaltrials.gov)
P2, N=26, Active, not recruiting, John Reneau | Trial completion date: Apr 2024 --> May 2025 | Trial primary completion date: Apr 2024 --> May 2025
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
lenalidomide • Adcetris (brentuximab vedotin)
1m
Report of six cases with mast cell leukemia and a literature review (PubMed, Zhonghua Nei Ke Za Zhi)
Two patients were treated with venetoclax and azacitidine for induction (one patient achieved partial remission by combination with afatinib, while there was no remission after combination with dasatinib in the other patient). Two patients did not achieve complete remission despite treatment with cladribine and imatinib, respectively...Overall, MCL is a rare subtype of systemic mastocytosis with heterogeneous clinical course, and these patients have poor outcome. A better understanding of the clinical characteristics, treatment, and prognosis of MCL is urgently needed.
Retrospective data • Review • Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IL2RA (Interleukin 2 receptor, alpha) • CD2 (CD2 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
|
TNFRSF8 positive
|
Venclexta (venetoclax) • Gilotrif (afatinib) • dasatinib • imatinib • azacitidine • cladribine
2ms
Trial completion
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
2ms
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides (clinicaltrials.gov)
P1, N=10, Recruiting, University of Alabama at Birmingham | Trial completion date: Jun 2025 --> Jul 2026 | Trial primary completion date: Dec 2024 --> Apr 2026
Trial completion date • Trial primary completion date • Combination therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin) • Poteligeo (mogamulizumab-kpkc)
2ms
Lymphomatoid Papulosis Type D in a Mestizo-Ancestry Man. (PubMed, Am J Dermatopathol)
The course of the disease is recurrent; however, the prognosis is good with a 10-year survival of 100%. We present the case of a mestizo-ancestry patient who developed a type-D LyP, and, to the best of our knowledge, there are no publications of type D LyP from Latin-American authors or about mestizo-ancestry (or hispanic) patients; therefore, we consider of relevance to inform about these findings.
Journal
|
CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • GZMB (Granzyme B)
|
TNFRSF8 positive
6ms
Ritlecitinib in CTCL (clinicaltrials.gov)
P2, N=20, Recruiting, Icahn School of Medicine at Mount Sinai | Phase classification: P2a --> P2
Phase classification
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Litfulo (ritlecitinib)
7ms
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas (clinicaltrials.gov)
P1, N=5, Active, not recruiting, Walter Hanel | Recruiting --> Active, not recruiting | N=20 --> 5 | Trial primary completion date: Dec 2023 --> Dec 2024
Enrollment closed • Enrollment change • Trial primary completion date • Combination therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Istodax (romidepsin) • parsaclisib (INCB50465)
7ms
CREDIT: A Study of Chinese Adults With Lymphoma (clinicaltrials.gov)
P=N/A, N=1000, Recruiting, Takeda | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Mar 2024 --> Jun 2024
Trial completion date • Trial primary completion date • Discordant
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 expression
7ms
Primary cutaneous anaplastic large-cell lymphoma resembling infratemporal space infection: a case report. (PubMed, BMC Oral Health)
This report suggests that if there are suspicious intraoperative manifestations, carrying out a biopsy simultaneously, using Hematoxylin and eosin (HE) staining, and a comprehensive Immunohistochemistry (IHC) panel are essential to diagnosing PC-ALCL to prevent misdiagnosis.
Journal
|
ALK (Anaplastic lymphoma kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • CRP (C-reactive protein)
|
ALK positive • TNFRSF8 positive
7ms
EATL-001: CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. (clinicaltrials.gov)
P2, N=14, Completed, Imagine Institute | Active, not recruiting --> Completed | N=25 --> 14 | Trial completion date: Feb 2024 --> Sep 2023
Trial completion • Enrollment change • Trial completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin) • carmustine
7ms
CD39 is expressed by a wide range of cutaneous T-cell lymphomas. (PubMed, Skin Health Dis)
CD39 was overexpressed by peripheral blood T-cells in Sezary syndrome and mycosis fungoides, and in skin-infiltrating lymphocytes of Sezary syndrome, mycosis fungoides, subcutaneous panniculitis-like T-cell lymphoma and primary cutaneous CD30-positive lymphoproliferation. Our study emphasizes the interest in using CD39/CD73/adenosine pathway blocking agents for cutaneous T cell lymphomas treatment.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • CD73 (5'-Nucleotidase Ecto) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
|
TNFRSF8 positive • ENTPD1 expression
8ms
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov)
P2, N=46, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Mar 2024 | Trial primary completion date: Sep 2025 --> Mar 2024
Trial completion • Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
8ms
Trial completion
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Opdivo (nivolumab) • cabiralizumab (BMS-986227)
8ms
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery (clinicaltrials.gov)
P2, N=55, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
Trial completion date • Trial primary completion date • Surgery
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 expression
|
Adcetris (brentuximab vedotin)
9ms
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc (clinicaltrials.gov)
P2, N=11, Recruiting, Lawson Health Research Institute | Not yet recruiting --> Recruiting | Trial completion date: Mar 2026 --> Jul 2026 | Trial primary completion date: Nov 2025 --> Feb 2026
Enrollment open • Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • IL2 (Interleukin 2)
|
TNFRSF8 positive
|
cyclophosphamide • Adcetris (brentuximab vedotin)
9ms
Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma. (PubMed, Am J Clin Pathol)
Positive CD30 expression was a favorable prognostic factor for ENKTL, and CD30 expression could restratify the survival of patients in clinical subgroups.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 expression
9ms
Anaplastic large cell lymphoma presenting as a mass in the uterine cervix: a case report. (PubMed, J Hematop)
Since ALCL may have a variable expression of T-cell antigens, the diagnosis may easily be missed when CD45 and/or CD3 is negative, and screening epithelial stains for carcinoma (e.g., p63 and EMA) are positive. CD30 must be performed to raise the consideration of ALCL when reniform nuclei are observed.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • TP63 (Tumor protein 63)
|
ALK rearrangement • TNFRSF8 positive • TNFRSF8 expression
9ms
Multicolor flow cytometric immunophenotyping is highly sensitive and specific in identifying aberrant mast cells in the diagnostic workup of systemic mastocytosis. (PubMed, Am J Clin Pathol)
Flow cytometric immunophenotyping is a quick, sensitive, high-yield tool for evaluating the immunophenotype of mast cells. An abnormal FCI finding should prompt careful histologic evaluation and sensitive KIT D816V mutation testing to address the possibility of SM. CD2, CD25, and CD30 are important markers for the detection of immunophenotypic aberrancy of mast cells, and their frequencies of aberrancy differ across SM subtypes.
Journal
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • IL2RA (Interleukin 2 receptor, alpha) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CD2 (CD2 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
|
TNFRSF8 positive • TNFRSF8 expression • KIT D816V
9ms
P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov)
P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • daunorubicin
9ms
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (clinicaltrials.gov)
P1, N=20, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=30 --> 20
Enrollment closed • Enrollment change
|
TNFRSF8 positive
|
lenalidomide • Istodax (romidepsin) • Onureg (azacitidine oral)
9ms
Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy. (PubMed, Virchows Arch)
In conclusion, 44% of ALCL patients, regardless of histological subtypes, showed a loss of/decrease in CD30 expression after receiving BV-containing therapy, but this phenomenon was not observed in CHL patients. A higher cumulative dose of BV and a lower amount of CD30 antigen in tumor cells in the initial biopsy materials might be predictors of a loss of/decrease in CD30 expression in ALCL patients.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • TNFRSF8 expression • ALK negative
|
Adcetris (brentuximab vedotin)
9ms
Primary Cutaneous CD30-Positive Lymphoproliferative Disorders-Current Therapeutic Approaches with a Focus on Brentuximab Vedotin. (PubMed, J Clin Med)
Recent years have seen the introduction of novel agents into clinical practice; most of these target CD30, such as anti-CD30 monoclonal antibodies and conjugated antibodies (brentuximab vedotin), bispecific antibodies and cellular therapies, particularly anti-CD30 CAR-T cells. This paper briefly reviews the biology of CD30 that makes it a good therapeutic target and describes the anti-CD30 therapies that have emerged to date.
Review • Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
10ms
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs). (PubMed, Blood)
These entities are currently treated similarly with CHOP or CHOEP for CD30-negative diseases or brentuximab vedotin plus CHP for CD30-positive diseases, followed by consolidation with autologous stem cell transplant in first remission...Although current treatment strategies lump most disease entities together, future treatment will include distinct strategies for each disease subtype that optimizes therapy for individuals. This movement towards individualized therapy will ultimately lead to dramatic improvements in prognosis for patients with PTCL.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 negative
|
Adcetris (brentuximab vedotin)
10ms
Trial completion
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
acimtamig (AFM13)
10ms
EBV-positive Nodal T-Cell and NK-Cell Lymphoma: A Study of 26 Cases Including a Subset With Strong CD30 Expression Mimicking Anaplastic Large Cell Lymphoma. (PubMed, Am J Surg Pathol)
Distinguishing between EBV+ nodal T-cell and NK-cell lymphoma from ALCL is important because treatment strategy and prognosis differ. CD30 expression offers a potential therapeutic target for patients with this aggressive disease.
Journal
|
CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
TNFRSF8 positive • TNFRSF8 expression
10ms
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
P2, N=23, Recruiting, Joseph Tuscano | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin) • bendamustine
10ms
Trial completion
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
10ms
Primary leptomeningeal CD30 positive diffuse large B cell lymphoma disguise as meningioma in a young adult. (PubMed, Int J Neurosci)
PLMLs usually present in the elderly with a short duration of illness. Herein, we describe a case of CD30 positive diffuse large B-cell PLML in a young 21-years-old male with review of literature.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
10ms
CD30 protects EBV-positive diffuse large B-cell lymphoma cells against mitochondrial dysfunction through BNIP3-mediated mitophagy. (PubMed, Cancer Lett)
Additionally, CRISPR BNIP3 knockout caused proliferation defects and increased sensitivity to apoptosis. All the findings reveal a strong relationship between mitophagy and adverse prognosis of EBV DLBCL and discover a new regulatory mechanism of BNIP3-mediated mitophagy, which may help develop effective treatment regimens with anti-CD30 antibody brentuximab vedotin to improve the prognosis of CD30 EBV DLBCL patients.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BNIP3 (BCL2 Interacting Protein 3)
|
TNFRSF8 positive • TNFRSF8 expression
|
Adcetris (brentuximab vedotin)
11ms
A Mouse Model to Study the Pathogenesis of γ-herpesviral Infections in Germinal Center B Cells. (PubMed, Cells)
While the LMP2A-expressing MHV-68 behaved similarly to wildtype MHV-68, virally induced constitutively active CD30-signaling in GC B cells led to the expansion of a pre-plasmablastic population. The findings underscore the potential of our novel tools to address crucial questions about the interaction between herpesviral infections and deregulated cellular gene-expression in future studies.
Preclinical • Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
11ms
Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review. (PubMed, Cancers (Basel))
In recent years, targeted therapies such as ALK inhibitors and brentuximab vedotin (BV) have been developed. Weekly vinblastine treatment and hematopoietic stem cell transplantation have also been reported to be effective therapies. This article reviews pediatric ALK-positive ALCL, focusing on risk factors and treatment strategies for pediatric patients with relapsed or refractory ALK-positive ALCL.
Review • Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • ALK mutation • TNFRSF8 positive • TNFRSF8 expression
|
Adcetris (brentuximab vedotin) • vinblastine
11ms
CD30 plays a role in T-dependent immune response and T cell proliferation. (PubMed, FASEB J)
High-throughput RNA sequencing analysis revealed that CD30 deficiency led to a decrease of FOXO-autophagy axis in T cells upon TCR stimulation. Thus, CD30 positively regulates T-cell-dependent immune response and T cell proliferation.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • TNFA (Tumor Necrosis Factor-Alpha)
|
TNFRSF8 positive • TNFRSF8 expression
11ms
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1/2, N=240, Recruiting, Genmab | Trial completion date: Jun 2028 --> Dec 2032
Trial completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
GEN3017
12ms
Characteristics and Prognosis of Epstein Barr Virus-Positive Diffuse Large B-Cell Lymphoma: A Retrospective, Single-Center Study (ASH 2023)
After treatment with rituximab combined with chemotherapy, the EBV+DLBCL patients had a complete response rate and a overall response rate of 55... The majority of EBV+DLBCL patients were non-GCB. β2-Microglobulin level and bone marrow invasion were independent risk factors for PFS in patients with EBV+DLBCL, while β2-Microglobulin and HB were independent risk factors for OS in patients with EBV+DLBCL. The therapeutical potentials of targeted medicines, such as CD30 inhibitors and PD-1 inhibitors, deserve to be explored in the future.
Retrospective data
|
B2M (Beta-2-microglobulin)
|
TNFRSF8 positive
|
Rituxan (rituximab)
12ms
Extracellular CD30 and ADAM10/17 Regulate Brentuximab Vedotin-Induced Cell Death in an Adult T-Cell Leukemia Cell Line (ASH 2023)
Moreover, endogenous extracellular CD30, such as sCD30 shed by ADAM10/17, and CD30-positive EVs may be responsible for the BV-induced cell death. Correctively, extracellular CD30 concentrations, including EV, may be useful as biomarkers for BV therapy in ATL.
Preclinical
|
TNFRSF8 (TNF Receptor Superfamily Member 8) • ADAM10 (ADAM Metallopeptidase Domain 10)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
12ms
Combining BCL-XL Inhibition with Brentuximab Vedotin to Overcome Chemoresistance in EBV-Related T/NK Lymphoma (ASH 2023)
MethodsA diverse panel of EBV+ T/NK lymphoma cell lines including SNK1, MECO4, SNK6, SNT8, SNK10, SNT15 and SNT16 were evaluated for sensitivity to MMAE alone and with specific BH3 family inhibitors including A1331852, inhibiting BCL-XL, venetoclax inhibiting and BCL-2 and the MCL-1 inhibitor S63845 (Generon). These data show the potential of BV with BCL-XL inhibition to be an effective and tolerable treatment for ENKTL. We are now planning a detailed preclinical study to better understand the efficacy and safety of this combination in vivo and progress towards a future clinical trial.
IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL2L1 (BCL2-like 1)
|
TNFRSF8 positive • TNFRSF8 expression
|
Venclexta (venetoclax) • Adcetris (brentuximab vedotin) • S63845 • A-1331852
12ms
A Survey of Brentuximab Vedotin in Pediatric Participants With Hodgkin Lymphoma (clinicaltrials.gov)
P=N/A, N=8, Recruiting, Takeda | Trial completion date: Jul 2027 --> Dec 2027 | Trial primary completion date: Jul 2027 --> Dec 2027
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
doxorubicin hydrochloride • Adcetris (brentuximab vedotin)
12ms
Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma" (clinicaltrials.gov)
P=N/A, N=113, Completed, Takeda | Trial completion date: Dec 2022 --> Sep 2023 | Trial primary completion date: Dec 2022 --> Sep 2023
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
12ms
Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" (clinicaltrials.gov)
P=N/A, N=95, Active, not recruiting, Takeda | Completed --> Active, not recruiting | Trial completion date: Sep 2023 --> Dec 2023
Enrollment closed • Trial completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
12ms
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK rearrangement • TNFRSF8 positive
12ms
A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study. (PubMed, Blood Res)
The most common side effect of BV was peripheral neuropathy; 22 patients (25.9%, 22/85) experienced peripheral neuropathy (all grades). s : The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)